TMDX Overview

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is147.80 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Transmedics Group Inc revenue for the last quarter amounts to 160.76M USD, increased 32.18

Transmedics Group Inc. EPS for the last quarter amounts to 2.58 USD, increased 1257.89

Transmedics Group Inc (TMDX) has 898 emplpoyees as of March 31 2026.

Today TMDX has the market capitalization of 3.24B USD.